Graves' Eye Disease

Current Location

24 Graves' Eye Disease Trials Near You

Power is an online platform that helps thousands of Graves' Eye Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Satralizumab for Thyroid Eye Disease

Columbus, Ohio
This trial is testing an injectable medicine called satralizumab for people with thyroid eye disease. The medicine works by blocking a protein that causes inflammation, which can help reduce swelling and discomfort in the eyes. The study aims to see how safe and effective this treatment is for these patients.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

127 Participants Needed

TOUR006 for Thyroid Eye Disease

Columbus, Ohio
This trial tests different amounts of a drug called TOUR006 in patients with active inflammation from Thyroid Eye Disease. The goal is to see if it can reduce inflammation and improve symptoms.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

81 Participants Needed

Batoclimab for Graves' Eye Disease

Columbus, Ohio
This trial tests batoclimab, a medication given as weekly injections under the skin, to see if it can help reduce eye bulging in patients with proptosis. The treatment starts with a higher dose for a few months, followed by a lower dose for a few more months. Batoclimab works by adjusting the immune system to decrease inflammation and swelling around the eyes.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting

100 Participants Needed

VRDN-001 for Thyroid Eye Disease

Huntington, West Virginia
This trial is testing VRDN-001, a medicine that blocks a part of cells causing inflammation, in patients with thyroid eye disease. The goal is to see if it can reduce eye swelling and inflammation.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

154 Participants Needed

Lonigutamab for Thyroid Eye Disease

Ann Arbor, Michigan
This trial is testing a new medication called lonigutamab to help people with Thyroid Eye Disease (TED). TED causes eye problems due to thyroid issues. Lonigutamab may work by reducing inflammation and other symptoms in the eyes.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

54 Participants Needed

Kamuvudine-9 for Thyroid Eye Disease

Lexington, Kentucky
The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 weeks with a primary endpoint of safety.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

13 Participants Needed

Linsitinib for Thyroid Eye Disease

Morgantown, West Virginia
This trial is testing linsitinib, a medication, on patients who did not improve or got worse after previous treatment. The goal is to see if linsitinib can help these patients by blocking certain proteins that make their condition worse.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

75 Participants Needed

Linsitinib for Thyroid Eye Disease

Ann Arbor, Michigan
This trial studies the safety and effectiveness of linsitinib, an oral medication taken regularly, in patients with moderate to severe thyroid eye disease. Linsitinib works by blocking a protein that contributes to the disease, aiming to reduce symptoms and improve eye health.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3

90 Participants Needed

VRDN-001 for Thyroid Eye Disease

Morgantown, West Virginia
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). The primary objective of this clinical trial is to evaluate the safety and tolerability of VRDN-001 in patients with TED.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

231 Participants Needed

VRDN-003 for Graves' Eye Disease

Morgantown, West Virginia
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

195 Participants Needed

VRDN-003 for Graves' Eye Disease

Morgantown, West Virginia
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

117 Participants Needed

Efgartigimod for Thyroid Eye Disease

Morgantown, West Virginia
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up observational period while off study drug. Some participants may also enter the open-label treatment period with efgartigimod PH20 SC. The study duration varies from approximately 60 to 110 weeks. An alternative list of clinical sites open for recruitment could be found in the other UplighTED study record (https://www.clinicaltrials.gov/study/NCT06307626)
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

108 Participants Needed

Teprotumumab for Graves' Eye Disease

Ann Arbor, Michigan
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

89 Participants Needed

Satralizumab for Thyroid Eye Disease

Morgantown, West Virginia
This trial is testing an injectable medicine called satralizumab for people with thyroid eye disease. The medicine works by blocking a protein that causes inflammation, which can help reduce swelling and discomfort in the eyes. The study aims to see how safe and effective this treatment is for these patients.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

131 Participants Needed

Batoclimab for Graves' Eye Disease

Morgantown, West Virginia
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

100 Participants Needed

Batoclimab for Thyroid Eye Disease

Morgantown, West Virginia
This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

180 Participants Needed

LASN01 for Thyroid Eye Disease

Livonia, Michigan
This trial is testing LASN01, a human protein-based medicine, in patients with thyroid eye disease. It aims to help those who haven't had certain treatments before and those who have already tried teprotumumab. The medicine works by blocking part of the immune system to reduce eye problems.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

41 Participants Needed

New Treatment for Graves' Eye Disease

Livonia, Michigan
An open-label study for participants who received VRDN-001 or placebo and were non-responders at end of the treatment period assessment (i.e., 15 weeks) in the VRDN-001-101 (THRIVE) and VRDN-001-301 (THRIVE-2) pivotal studies
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

143 Participants Needed

VRDN-001 for Thyroid Eye Disease

Livonia, Michigan
This trial tests VRDN-001, a medicine that blocks a harmful protein, in people with long-term thyroid-related eye problems. The goal is to see if it is safe and effective in reducing symptoms.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

188 Participants Needed

VRDN-003 for Thyroid Eye Disease

Fraser, Michigan
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

284 Participants Needed

Why Other Patients Applied

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

Efgartigimod for Thyroid Eye Disease

Louisville, Kentucky
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up observational period while off study drug. Some participants may also enter the open-label treatment period with efgartigimod PH20 SC. The study duration varies from approximately 60 to 110 weeks. An alternative list of clinical sites open for recruitment could be found in the other UplighTED study record (https://www.clinicaltrials.gov/study/NCT06307613)
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

108 Participants Needed

Teprotumumab for Thyroid Eye Disease

Milwaukee, Wisconsin
This trial tests the safety and effectiveness of teprotumumab, an IV medication, in adults with Thyroid Eye Disease. It aims to find the best treatment period and assess the need for additional treatment. The medication helps by reducing inflammation and tissue changes in the eyes. Teprotumumab, initially developed for tumor treatment, was later repurposed for thyroid eye disease and approved by the USFDA.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

313 Participants Needed

Anti-VEGF Therapy for Thyroid Eye Disease

Boston, Massachusetts
This trial is testing the safety of injecting a medication called aflibercept, mixed with either a saltwater solution or an enzyme, around the eyes of patients with acute Thyroid Eye Disease. The goal is to see if this treatment can safely reduce swelling and inflammation. Patients will receive multiple injections and be monitored for any side effects. Aflibercept has been used in various retinal diseases, including macular edema and age-related macular degeneration.
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

24 Participants Needed

AMG 732 for Thyroid Eye Disease

Jacksonville, Florida
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65

88 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Graves' Eye Disease clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Graves' Eye Disease clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Graves' Eye Disease trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Graves' Eye Disease is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Graves' Eye Disease medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Graves' Eye Disease clinical trials?

Most recently, we added VRDN-003 for Thyroid Eye Disease, Kamuvudine-9 for Thyroid Eye Disease and VRDN-003 for Graves' Eye Disease to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Osteoarthritis Knee Clinical Trials

Top Clinical Trials near Irving, TX

203 Clinical Trials near Encinitas, CA

Top Clinical Trials near Bismark, ND

Top Clinical Trials near Canton, IL

Top Vitamin D Deficiency Clinical Trials

Top Microbiome Clinical Trials

Top Clinical Trials near Creston, IA

Top Mental Illness Clinical Trials

229 Clinical Trials near Bronxville, NY

Top Clinical Trials near Jackson, MS

Top Nasopharyngeal Carcinoma Clinical Trials

By Trial

Contrast-Enhanced Ultrasound for Breast Cancer

Atenolol for Osteoporosis Prevention

Triptorelin for Cancer

Endoscopic Knives for Gastrointestinal Cancer

Tenapanor for Constipation · Recruiting Participants for Phase Phase 2 Clinical Trial 2025 | Power | Power

Fecal Microbiota Transplant for Ulcerative Colitis

Adaptive Naming Treatment Schedules for Aphasia

STN1010904 Eye Drops for Fuchs' Dystrophy

Collaborative Care Enhancement for Mental Health

Thulium Fiber Laser for Kidney Stones

Carfilzomib + Sotorasib for Lung Cancer

IMC-F106C vs Nivolumab for Melanoma

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial